首页 > 最新文献

Actas dermo-sifiliograficas最新文献

英文 中文
Melanoma diagnosis with 3D total-body photography.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-28 DOI: 10.1016/j.ad.2024.09.030
A Ferreirinha, V Farricha, A L João

Skin cancer is a growing global health challenge, emphasizing the need for early detection. In recent years, 3D total-body photography has emerged as a promising tool in dermatology. This non-invasive imaging technique provides a comprehensive visual representation of a patient's skin, enabling the early detection of suspicious lesions and the surveillance of existing nevi. Despite its promising role in early melanoma detection, ongoing research is essential to validate its real-world impact and address its current limitations. Although it enhances diagnostic accuracy, this technique currently does not replace the need for a thorough examination by a dermatologist. This review provides a comprehensive overview of the most recent findings on the application of 3D total-body photography in melanoma diagnosis.

皮肤癌是一个日益严重的全球性健康挑战,因此需要及早发现。近年来,三维全身摄影已成为皮肤科领域一种前景广阔的工具。这种无创成像技术能全面直观地显示患者的皮肤状况,从而及早发现可疑病变,并对现有痣进行监测。尽管该技术在早期黑色素瘤检测方面大有可为,但要验证其对现实世界的影响并解决其目前存在的局限性,仍需进行持续的研究。虽然这项技术提高了诊断的准确性,但目前还不能取代皮肤科医生进行全面检查的需要。本综述全面概述了三维全身摄影在黑色素瘤诊断中应用的最新研究成果。
{"title":"Melanoma diagnosis with 3D total-body photography.","authors":"A Ferreirinha, V Farricha, A L João","doi":"10.1016/j.ad.2024.09.030","DOIUrl":"https://doi.org/10.1016/j.ad.2024.09.030","url":null,"abstract":"<p><p>Skin cancer is a growing global health challenge, emphasizing the need for early detection. In recent years, 3D total-body photography has emerged as a promising tool in dermatology. This non-invasive imaging technique provides a comprehensive visual representation of a patient's skin, enabling the early detection of suspicious lesions and the surveillance of existing nevi. Despite its promising role in early melanoma detection, ongoing research is essential to validate its real-world impact and address its current limitations. Although it enhances diagnostic accuracy, this technique currently does not replace the need for a thorough examination by a dermatologist. This review provides a comprehensive overview of the most recent findings on the application of 3D total-body photography in melanoma diagnosis.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining omalizumab discontinuation in chronic spontaneous urticaria: the value of optimization and predictive factors of relapse. A 52-week multicenter study.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-28 DOI: 10.1016/j.ad.2024.08.014
J Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, N Fernández Chico, A Lara Moya, I Bielsa, P Ribó, B Mascaró-Hereza, M Bonfill-Ortí, J Spertino, E Serra, C Baliu-Piqué, G Melé-Ninot

Background: Patients with chronic spontaneous urticaria frequently relapse after discontinuing omalizumab and require its reintroduction. Although prior optimization might reduce recurrences, there is scarce evidence on this issue. Moreover; predictors of relapse have been identified in non-optimized patients before suspension.

Methods: We conducted a multicenter retrospective study with patients who discontinued omalizumab after optimization at a 12-month follow-up. Univariate and multivariate (tree classification method and Cox regression) analyses were performed.

Results: A total of 131 patients were included, 32.8% of whom relapsed after 12 months. Relapsed patients had longer disease duration (24.00 vs 11.00 months; p = 0.032), quicker response to standard dosage (1.00 vs. 3.00 months;; p = 0.014), fewer complete responses pre-optimization (83.70% vs 95.50%; p = 0.023), and shorter treatment duration at 300 mg/4 weeks (6 vs 7 months; p = 0.035). Multivariate analysis revealed that patients with low baseline C-reactive protein (CRP) and total immunoglobulin E (IgE) who underwent prolonged treatment were more likely to maintain a sustained remission at 12 months.

Conclusion: Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300 mg/4 weeks followed by an 18-month dose tapering is proposed.

背景:慢性自发性荨麻疹患者在停用奥马珠单抗后经常复发,需要重新使用奥马珠单抗。虽然事先优化可减少复发,但这方面的证据很少。此外,在停药前未经优化的患者中也发现了复发的预测因素:我们对优化后停用奥马珠单抗的患者进行了一项多中心回顾性研究,随访 12 个月。结果:共纳入 131 例患者:结果:共纳入131名患者,其中32.8%的患者在12个月后复发。复发患者的病程较长(24.00 个月 vs 11.00 个月;p = 0.032),对标准剂量的反应较快(1.00 个月 vs 3.00 个月;p = 0.014),优化前的完全反应较少(83.70% vs 95.50%;p = 0.023),300 毫克/4 周的治疗时间较短(6 个月 vs 7 个月;p = 0.035)。多变量分析显示,基线C反应蛋白(CRP)和总免疫球蛋白E(IgE)较低的患者接受长期治疗更有可能在12个月后保持持续缓解:结论:优化治疗似乎可以降低停药后的复发率。与复发最相关的因素与不同剂量奥马珠单抗的治疗时间以及基线 CRP 和总 IgE 水平有关。为了尽量减少停药后的复发,建议采用为期 12 个月的 300 毫克/4 周的治疗方案,然后再进行为期 18 个月的剂量递减。
{"title":"Redefining omalizumab discontinuation in chronic spontaneous urticaria: the value of optimization and predictive factors of relapse. A 52-week multicenter study.","authors":"J Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, N Fernández Chico, A Lara Moya, I Bielsa, P Ribó, B Mascaró-Hereza, M Bonfill-Ortí, J Spertino, E Serra, C Baliu-Piqué, G Melé-Ninot","doi":"10.1016/j.ad.2024.08.014","DOIUrl":"https://doi.org/10.1016/j.ad.2024.08.014","url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic spontaneous urticaria frequently relapse after discontinuing omalizumab and require its reintroduction. Although prior optimization might reduce recurrences, there is scarce evidence on this issue. Moreover; predictors of relapse have been identified in non-optimized patients before suspension.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective study with patients who discontinued omalizumab after optimization at a 12-month follow-up. Univariate and multivariate (tree classification method and Cox regression) analyses were performed.</p><p><strong>Results: </strong>A total of 131 patients were included, 32.8% of whom relapsed after 12 months. Relapsed patients had longer disease duration (24.00 vs 11.00 months; p = 0.032), quicker response to standard dosage (1.00 vs. 3.00 months;; p = 0.014), fewer complete responses pre-optimization (83.70% vs 95.50%; p = 0.023), and shorter treatment duration at 300 mg/4 weeks (6 vs 7 months; p = 0.035). Multivariate analysis revealed that patients with low baseline C-reactive protein (CRP) and total immunoglobulin E (IgE) who underwent prolonged treatment were more likely to maintain a sustained remission at 12 months.</p><p><strong>Conclusion: </strong>Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300 mg/4 weeks followed by an 18-month dose tapering is proposed.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperhidrosis, anticholinergics, and dementia.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-28 DOI: 10.1016/j.ad.2024.11.026
J Del Boz, J C Bautista Vidal

In recent decades, the use of certain oral anticholinergics for the treatment of hyperhidrosis has become widespread, often off-label but supported by multiple studies, including clinical trials, demonstrating their effectiveness and an apparently good safety profile. Similarly, various studies published in recent years have associated the use of anticholinergics to the development of dementia, particularly in elderly patients. Additionally, other studies have suggested that hyperhidrosis itself may be an early symptom of developing dementia. However, to date, no research has specifically linked the use of oral anticholinergics for hyperhidrosis treatment with the development of dementia. We present the currently available data on this controversial topic.

{"title":"Hyperhidrosis, anticholinergics, and dementia.","authors":"J Del Boz, J C Bautista Vidal","doi":"10.1016/j.ad.2024.11.026","DOIUrl":"https://doi.org/10.1016/j.ad.2024.11.026","url":null,"abstract":"<p><p>In recent decades, the use of certain oral anticholinergics for the treatment of hyperhidrosis has become widespread, often off-label but supported by multiple studies, including clinical trials, demonstrating their effectiveness and an apparently good safety profile. Similarly, various studies published in recent years have associated the use of anticholinergics to the development of dementia, particularly in elderly patients. Additionally, other studies have suggested that hyperhidrosis itself may be an early symptom of developing dementia. However, to date, no research has specifically linked the use of oral anticholinergics for hyperhidrosis treatment with the development of dementia. We present the currently available data on this controversial topic.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should hydroxyisohexyl 3-cyclohexene carboxaldehyde (LYRAL) still be part of the standard patch test series?
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-28 DOI: 10.1016/j.ad.2024.10.063
C P Hernández Fernández, L Borrego, A M Giménez Arnau, T Sanz Sánchez, J M Carrascosa Carrillo, V Zaragoza Ninet, E Serra Baldrich, F J Miquel Miquel, J F Silvestre Salvador, S Córdoba Guijarro, A Sánchez Gilo, P Mercader García, F Navarro Triviño, F Tous Romero, M Rodríguez Serna, G Melé Ninot, I Ruiz González, E Gómez de la Fuente, M A Pastor Nieto, P Sánchez-Pedreño Guillén, J Sánchez Pérez, J J Pereyra Rodríguez, M E Gatica Ortega, R González Pérez, I García Doval, M A Gallego Descalzo

Background and objectives: Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyral® is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021. We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish standard path test series.

Material and method: We analysed all consecutive patients simultaneously patch-tested with HICC and FM II from the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 through December 31st, 2023.

Results: A total of 96 (0.8%) out of 12,029 patients analyzed tested positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II were patched.

Conclusions: Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish standard patch test series and support its exclusion from the European standard patch test series.

背景和目标:羟基异己基-3-环己烯羧醛(HICC)或 Lyral® 是一种香料标记物,是香料混合 II(FM II)的一部分,尽管欧盟委员会已于 2021 年禁止在化妆品中使用该标记物,但该标记物仍作为一种独立的过敏原被纳入欧洲和其他基线系列。我们旨在研究 HICC 在西班牙的致敏率及其与 FM II 的同时阳性率,以确定其是否应成为西班牙标准路径测试系列的一部分:我们分析了西班牙接触性皮炎登记处(REIDAC)从2018年6月1日至2023年12月31日期间同时接受HICC和FM II贴片测试的所有连续患者:在分析的 12,029 名患者中,共有 96 人(0.8%)对 HICC 检测呈阳性,396 人(3.3%)对 FM II 检测呈阳性。分别有 53% 和 64% 的患者的检测结果被认为与当前病情相关。如果只对 FM II 进行修补,96 例 HICC 阳性患者中将有 72 例(75%)被检测出来:西班牙的 HICC 致敏率较低,近年来有所下降。HICC 是化妆品中的禁用香料,而 FM II 能检测出四分之三的致敏患者。我们的研究结果表明,HICC 仍不应纳入西班牙标准斑贴试验系列,并支持将其排除在欧洲标准斑贴试验系列之外。
{"title":"Should hydroxyisohexyl 3-cyclohexene carboxaldehyde (LYRAL) still be part of the standard patch test series?","authors":"C P Hernández Fernández, L Borrego, A M Giménez Arnau, T Sanz Sánchez, J M Carrascosa Carrillo, V Zaragoza Ninet, E Serra Baldrich, F J Miquel Miquel, J F Silvestre Salvador, S Córdoba Guijarro, A Sánchez Gilo, P Mercader García, F Navarro Triviño, F Tous Romero, M Rodríguez Serna, G Melé Ninot, I Ruiz González, E Gómez de la Fuente, M A Pastor Nieto, P Sánchez-Pedreño Guillén, J Sánchez Pérez, J J Pereyra Rodríguez, M E Gatica Ortega, R González Pérez, I García Doval, M A Gallego Descalzo","doi":"10.1016/j.ad.2024.10.063","DOIUrl":"https://doi.org/10.1016/j.ad.2024.10.063","url":null,"abstract":"<p><strong>Background and objectives: </strong>Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyral® is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021. We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish standard path test series.</p><p><strong>Material and method: </strong>We analysed all consecutive patients simultaneously patch-tested with HICC and FM II from the Spanish Contact Dermatitis Registry (REIDAC) from June 1<sup>st</sup>, 2018 through December 31<sup>st</sup>, 2023.</p><p><strong>Results: </strong>A total of 96 (0.8%) out of 12,029 patients analyzed tested positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II were patched.</p><p><strong>Conclusions: </strong>Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish standard patch test series and support its exclusion from the European standard patch test series.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary Intention Healing Time of Postoperative Surgical Cancer Skin Wounds With a Biosynthetic Porcine Type I Collagen Dressing: A 306-Patient Retrospective, Observational Study.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-25 DOI: 10.1016/j.ad.2025.02.022
A Gavillero Martín, M Juliá Roca, I Serra-Guillén, A Rodríguez-Hernández, E Manrique-Silva, A E López-Sundh, E Nagore Enguídanos

Background: Biosynthetic porcine type I collagen dressing is useful to close ulcers and secondary intention healing of surgical cancer wounds.

Objective: To identify factors associated with the healing time of such wounds.

Methods: We conducted a retrospective observational study of patients on oncological dermatological surgery in a cancer center. Healing time was studied based on age, sex, personal history of comorbidities, usual medication, anatomical location, type of surgery performed and size of the defect. Statistical analysis was performed using the ANOVA test and logistic regression.

Results: A total of 306 patients were included with a median age of 73 years (62.4%, men). The statistically significantly characteristics associated with a healing time ≤ 66 days were location-auricle, nose, inner canthus, hand, retroauricular region and nail bed-use of the Mohs technique and defect sizes ≤ 5.28 cm2.

Limitations: This is a retrospective study from a single center.

Conclusion: The use of biosynthetic porcine type I collagen dressings for the definitive closure of dermatological surgical cancer wounds seems particularly suitable for small defects of the inner canthus of the eye, hand, auricle, nose, forehead, retroauricular region, and nail bed.

背景:生物合成猪 I 型胶原敷料可用于闭合溃疡和外科癌症伤口的二次意向愈合:确定与此类伤口愈合时间相关的因素:我们对一家癌症中心的皮肤科肿瘤手术患者进行了一项回顾性观察研究。根据年龄、性别、个人合并症病史、常用药物、解剖位置、手术类型和缺损大小对愈合时间进行了研究。统计分析采用方差分析和逻辑回归法:共纳入 306 名患者,中位年龄为 73 岁(62.4% 为男性)。从统计学角度看,与愈合时间≤66天相关的特征是位置--耳廓、鼻、内眦、手、耳后区域和甲床--莫氏技术的使用和缺损面积≤5.28平方厘米:局限性:这是一项来自单一中心的回顾性研究:结论:使用生物合成猪 I 型胶原蛋白敷料用于皮肤外科癌症伤口的最终闭合,似乎特别适用于眼眶内侧、手部、耳廓、鼻部、前额、耳后区域和甲床的小缺损。
{"title":"Secondary Intention Healing Time of Postoperative Surgical Cancer Skin Wounds With a Biosynthetic Porcine Type I Collagen Dressing: A 306-Patient Retrospective, Observational Study.","authors":"A Gavillero Martín, M Juliá Roca, I Serra-Guillén, A Rodríguez-Hernández, E Manrique-Silva, A E López-Sundh, E Nagore Enguídanos","doi":"10.1016/j.ad.2025.02.022","DOIUrl":"https://doi.org/10.1016/j.ad.2025.02.022","url":null,"abstract":"<p><strong>Background: </strong>Biosynthetic porcine type I collagen dressing is useful to close ulcers and secondary intention healing of surgical cancer wounds.</p><p><strong>Objective: </strong>To identify factors associated with the healing time of such wounds.</p><p><strong>Methods: </strong>We conducted a retrospective observational study of patients on oncological dermatological surgery in a cancer center. Healing time was studied based on age, sex, personal history of comorbidities, usual medication, anatomical location, type of surgery performed and size of the defect. Statistical analysis was performed using the ANOVA test and logistic regression.</p><p><strong>Results: </strong>A total of 306 patients were included with a median age of 73 years (62.4%, men). The statistically significantly characteristics associated with a healing time ≤ 66 days were location-auricle, nose, inner canthus, hand, retroauricular region and nail bed-use of the Mohs technique and defect sizes ≤ 5.28 cm<sup>2</sup>.</p><p><strong>Limitations: </strong>This is a retrospective study from a single center.</p><p><strong>Conclusion: </strong>The use of biosynthetic porcine type I collagen dressings for the definitive closure of dermatological surgical cancer wounds seems particularly suitable for small defects of the inner canthus of the eye, hand, auricle, nose, forehead, retroauricular region, and nail bed.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin Homeostasis is Impaired in Hidradenitis Suppurativa Lesions: A Comparative Study.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-21 DOI: 10.1016/j.ad.2025.02.019
A Soto-Moreno, N Delgado-Moya, M Sánchez-Díaz, S Arias-Santiago, A Molina-Leyva

Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease whose impact on skin homeostasis has not been adequately studied at present. Knowledge about how skin function changes in these patients, and could be of interest not only to improve the topical management of the disease, but also as an objective measure of disease activity. The aim of this study was to compare skin homeostasis and the epidermal barrier function in lesional and healthy skin areas of patients with HS.

Methods: We conducted a cross-sectional study. Skin homeostasis and the epidermal barrier function of lesions were assessed in HS patients using validated tools. A healthy perilesional skin control was assigned to each lesion to compare skin homeostasis parameters.

Results: A total of 43 patients were included: 22 nodules, 10 abscesses and 25 draining tunnels were measured. The male-to-female ratio was 20:23, and the mean age, 35.95 years (SD, 14.82). Increased transepidermal water loss (TEWL) and erythema were found in nodules, abscesses and draining tunnel vs healthy skin. A direct association was observed between inflammatory nodules TEWL and IHS4 stage. In draining tunnels, a direct association was observed between TEWL and smoking. A trend of increasing TEWL values was observed as a function of Hurley stage.

Conclusion: HS lesions exhibit epidermal barrier dysfunction that depends on the severity of inflammatory activity. These results could be useful to develop objective classification systems for the severity and degree of involvement of HS or help in the development of vehicles for specific drugs, antiseptics and dressings for the management of this disease.

{"title":"Skin Homeostasis is Impaired in Hidradenitis Suppurativa Lesions: A Comparative Study.","authors":"A Soto-Moreno, N Delgado-Moya, M Sánchez-Díaz, S Arias-Santiago, A Molina-Leyva","doi":"10.1016/j.ad.2025.02.019","DOIUrl":"https://doi.org/10.1016/j.ad.2025.02.019","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic skin disease whose impact on skin homeostasis has not been adequately studied at present. Knowledge about how skin function changes in these patients, and could be of interest not only to improve the topical management of the disease, but also as an objective measure of disease activity. The aim of this study was to compare skin homeostasis and the epidermal barrier function in lesional and healthy skin areas of patients with HS.</p><p><strong>Methods: </strong>We conducted a cross-sectional study. Skin homeostasis and the epidermal barrier function of lesions were assessed in HS patients using validated tools. A healthy perilesional skin control was assigned to each lesion to compare skin homeostasis parameters.</p><p><strong>Results: </strong>A total of 43 patients were included: 22 nodules, 10 abscesses and 25 draining tunnels were measured. The male-to-female ratio was 20:23, and the mean age, 35.95 years (SD, 14.82). Increased transepidermal water loss (TEWL) and erythema were found in nodules, abscesses and draining tunnel vs healthy skin. A direct association was observed between inflammatory nodules TEWL and IHS4 stage. In draining tunnels, a direct association was observed between TEWL and smoking. A trend of increasing TEWL values was observed as a function of Hurley stage.</p><p><strong>Conclusion: </strong>HS lesions exhibit epidermal barrier dysfunction that depends on the severity of inflammatory activity. These results could be useful to develop objective classification systems for the severity and degree of involvement of HS or help in the development of vehicles for specific drugs, antiseptics and dressings for the management of this disease.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-21 DOI: 10.1016/j.ad.2025.02.020
D Flor, C Montero-Vilchez, T Montero-Vilchez, S Arias-Santiago, M Gonçalo

Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.

The objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.

Methods: We conducted a multicenter, prospective, observational study from 2018 through 2022 with adolescent and adult patients with moderate-to-severe atopic dermatitis treated with dupilumab from Hospital Universitario Virgen de las Nieves, Spain, and Coimbra University Hospital, Portugal. Clinical scoring of the dermatitis, complete blood count, total serum IgE and LDH levels were collected at baseline and on weeks 8, 16, 24 and 48.

Results: We included a total of 81 patients (41 women/40 men; mean age of 30.86 ± 12.26 years). Clinical and demographic characteristics were similar across centres. AD severity scales (EASI, SCORAD, ItchVAS and SleepVAS) showed sustained improvement from week 8 of treatment onwards. Eosinophil levels were significantly higher on week 16 (0.69 x103/μL) vs baseline (0.41 x103/μL) (p = 0.018) and returned to baseline levels on week 48 (0.59 x103/μL, p > 0.05). LDH and IgE levels decreased during the study.

Conclusion: Our study showed a significant clinical improvement of AD but a mild and self-limited increase in eosinophil levels on week 16, not associated with any clinical signs. Therefore, elevated serum eosinophil levels in AD patients on dupilumab does not seem clinically relevant and should not condition treatment withdrawal.

简介杜匹鲁单抗是一种IL-4/IL-13抑制剂单克隆抗体,已被批准用于治疗中重度特应性皮炎(AD),具有显著的安全性和有效性。本研究的目的是评估使用杜匹单抗期间血液嗜酸性粒细胞和其他实验室指标的变化:从2018年到2022年,我们开展了一项多中心、前瞻性、观察性研究,研究对象是接受杜必鲁单抗治疗的中重度特应性皮炎青少年和成人患者,他们分别来自西班牙圣女大学医院(Hospital Universitario Virgen de las Nieves)和葡萄牙科英布拉大学医院(Coimbra University Hospital)。我们在基线和第 8、16、24 和 48 周收集了皮炎临床评分、全血细胞计数、血清总 IgE 和 LDH 水平:我们共纳入了 81 名患者(41 名女性/40 名男性;平均年龄为 30.86 ± 12.26 岁)。各中心的临床和人口统计学特征相似。AD严重程度量表(EASI、SCORAD、ItchVAS和SleepVAS)显示,从治疗的第8周开始,AD症状持续改善。嗜酸性粒细胞水平在第16周(0.69 x103/μL)明显高于基线(0.41 x103/μL)(p = 0.018),并在第48周恢复到基线水平(0.59 x103/μL,p > 0.05)。LDH和IgE水平在研究期间有所下降:我们的研究表明,AD 的临床症状明显改善,但嗜酸性粒细胞水平在第 16 周出现了轻度和自限性升高,且与任何临床症状无关。因此,服用杜必鲁单抗的 AD 患者血清嗜酸性粒细胞水平升高似乎与临床无关,不应作为停药的条件。
{"title":"Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis.","authors":"D Flor, C Montero-Vilchez, T Montero-Vilchez, S Arias-Santiago, M Gonçalo","doi":"10.1016/j.ad.2025.02.020","DOIUrl":"https://doi.org/10.1016/j.ad.2025.02.020","url":null,"abstract":"<p><strong>Introduction: </strong>Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.</p><p><strong>The objective: </strong>of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.</p><p><strong>Methods: </strong>We conducted a multicenter, prospective, observational study from 2018 through 2022 with adolescent and adult patients with moderate-to-severe atopic dermatitis treated with dupilumab from Hospital Universitario Virgen de las Nieves, Spain, and Coimbra University Hospital, Portugal. Clinical scoring of the dermatitis, complete blood count, total serum IgE and LDH levels were collected at baseline and on weeks 8, 16, 24 and 48.</p><p><strong>Results: </strong>We included a total of 81 patients (41 women/40 men; mean age of 30.86 ± 12.26 years). Clinical and demographic characteristics were similar across centres. AD severity scales (EASI, SCORAD, ItchVAS and SleepVAS) showed sustained improvement from week 8 of treatment onwards. Eosinophil levels were significantly higher on week 16 (0.69 x10<sup>3</sup>/μL) vs baseline (0.41 x10<sup>3</sup>/μL) (p = 0.018) and returned to baseline levels on week 48 (0.59 x10<sup>3</sup>/μL, p > 0.05). LDH and IgE levels decreased during the study.</p><p><strong>Conclusion: </strong>Our study showed a significant clinical improvement of AD but a mild and self-limited increase in eosinophil levels on week 16, not associated with any clinical signs. Therefore, elevated serum eosinophil levels in AD patients on dupilumab does not seem clinically relevant and should not condition treatment withdrawal.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review on dietary supplements in the prevention and/or treatment of actinic keratosis and field cancerization.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-21 DOI: 10.1016/j.ad.2024.12.019
A Rodríguez-Luna, A Zamarrón, C Longo, G Pellacani, K Peris, P Calzavara-Pinton, M V de Galvez, Y Gilaberte, M de Troya, Á Juarranz, Salvador González

Background: Actinic keratoses (AKs) are chronic, recurrent precancerous lesions primarily induced by long-term sun exposure, commonly found on sun-exposed areas such as the face, neck, hands, forearms, and lower legs. AKs are prevalent, affecting millions worldwide, and pose a significant risk of transforming into invasive squamous cell carcinomas (SCCs).

Objective: This systematic review aims to update the scientific evidence on the role of oral bioactives, nutraceuticals, or dietary supplements in the treatment of AKs and field cancerization, while evaluating their safety and efficacy profile.

Methods: A review plan was pre-registered in the PROSPERO database (CRD42023485985). Following the PRISMA guidelines, we identified, selected, and included relevant studies. We screened a total of 234 articles, thoroughly reviewed 38 full texts, and ultimately included 21 articles published from 2013 through 2023 for analysis.

Results: The selected studies were categorized into 3 groups based on the chemical nature of the supplements: polyphenols (11 studies), vitamins (8 studies), and others (2 studies). The studies included preclinical (9) and clinical (12) studies. Clinical trials have demonstrated the efficacy profile of polyphenolic supplements, such as Polypodium leucotomos extract (PLE) and others in improving skin health and reducing the risk of skin cancers. Preclinical studies highlighted the protective effects of polyphenols against UV-induced damage and neoplastic transformation. Vitamin supplementation studies revealed mixed results, with clear data showing benefits in reducing the risk of precancerous lesions and skin cancers after nicotinamide (NAM) treatment, while others did not demonstrate significant protective effects.

Conclusions: The review confirms the efficacy of polyphenols in preventing and treating AKs and related skin conditions. However, the role of vitamins and other supplements requires further investigation due to inconsistent and/or scarce findings. Future clinical trials should focus on diverse populations at higher risk of skin cancer and explore new ingredients as well as combinations of various ingredients to optimize therapeutic applications.

{"title":"Systematic review on dietary supplements in the prevention and/or treatment of actinic keratosis and field cancerization.","authors":"A Rodríguez-Luna, A Zamarrón, C Longo, G Pellacani, K Peris, P Calzavara-Pinton, M V de Galvez, Y Gilaberte, M de Troya, Á Juarranz, Salvador González","doi":"10.1016/j.ad.2024.12.019","DOIUrl":"https://doi.org/10.1016/j.ad.2024.12.019","url":null,"abstract":"<p><strong>Background: </strong>Actinic keratoses (AKs) are chronic, recurrent precancerous lesions primarily induced by long-term sun exposure, commonly found on sun-exposed areas such as the face, neck, hands, forearms, and lower legs. AKs are prevalent, affecting millions worldwide, and pose a significant risk of transforming into invasive squamous cell carcinomas (SCCs).</p><p><strong>Objective: </strong>This systematic review aims to update the scientific evidence on the role of oral bioactives, nutraceuticals, or dietary supplements in the treatment of AKs and field cancerization, while evaluating their safety and efficacy profile.</p><p><strong>Methods: </strong>A review plan was pre-registered in the PROSPERO database (CRD42023485985). Following the PRISMA guidelines, we identified, selected, and included relevant studies. We screened a total of 234 articles, thoroughly reviewed 38 full texts, and ultimately included 21 articles published from 2013 through 2023 for analysis.</p><p><strong>Results: </strong>The selected studies were categorized into 3 groups based on the chemical nature of the supplements: polyphenols (11 studies), vitamins (8 studies), and others (2 studies). The studies included preclinical (9) and clinical (12) studies. Clinical trials have demonstrated the efficacy profile of polyphenolic supplements, such as Polypodium leucotomos extract (PLE) and others in improving skin health and reducing the risk of skin cancers. Preclinical studies highlighted the protective effects of polyphenols against UV-induced damage and neoplastic transformation. Vitamin supplementation studies revealed mixed results, with clear data showing benefits in reducing the risk of precancerous lesions and skin cancers after nicotinamide (NAM) treatment, while others did not demonstrate significant protective effects.</p><p><strong>Conclusions: </strong>The review confirms the efficacy of polyphenols in preventing and treating AKs and related skin conditions. However, the role of vitamins and other supplements requires further investigation due to inconsistent and/or scarce findings. Future clinical trials should focus on diverse populations at higher risk of skin cancer and explore new ingredients as well as combinations of various ingredients to optimize therapeutic applications.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary Intention Healing After Mohs Micrographic Surgery: An Updated Review of Classic and Novel Applications, Benefits and Complications.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-21 DOI: 10.1016/j.ad.2025.02.021
Javier Gil-Lianes, Ignasi Marti-Marti, Daniel Morgado-Carrasco

Although secondary intention healing (SIH) is a fundamental aspect of postoperative care following Mohs micrographic ssurgery (MMS), it is currently underutilized. SIH constitutes a safe, cost-effective, and versatile method for wound closure. SIH offers multiple advantages, including enhanced cancer surveillance, reduced pain, and promosing esthetic outcomes, particularly not only on certain anatomical regions such as the medial canthus, antihelix, temple, or alar crease, but also for relatively small and superficial defects on the eyelids, ears, lips, and nose, including the alar region, and defects on the hands dorsal regions. Careful patient selection and thorough risk assessment are imperative to mitigate potential complications, including retraction, hyper/hypopigmented scars, or delayed healing. This comprehensive review aims to inform evidence-based decision-making on the role of SIH in MMS, synthesizing its indications, advantages, complications, wound care, and integration with other reconstructive methods.

{"title":"Secondary Intention Healing After Mohs Micrographic Surgery: An Updated Review of Classic and Novel Applications, Benefits and Complications.","authors":"Javier Gil-Lianes, Ignasi Marti-Marti, Daniel Morgado-Carrasco","doi":"10.1016/j.ad.2025.02.021","DOIUrl":"https://doi.org/10.1016/j.ad.2025.02.021","url":null,"abstract":"<p><p>Although secondary intention healing (SIH) is a fundamental aspect of postoperative care following Mohs micrographic ssurgery (MMS), it is currently underutilized. SIH constitutes a safe, cost-effective, and versatile method for wound closure. SIH offers multiple advantages, including enhanced cancer surveillance, reduced pain, and promosing esthetic outcomes, particularly not only on certain anatomical regions such as the medial canthus, antihelix, temple, or alar crease, but also for relatively small and superficial defects on the eyelids, ears, lips, and nose, including the alar region, and defects on the hands dorsal regions. Careful patient selection and thorough risk assessment are imperative to mitigate potential complications, including retraction, hyper/hypopigmented scars, or delayed healing. This comprehensive review aims to inform evidence-based decision-making on the role of SIH in MMS, synthesizing its indications, advantages, complications, wound care, and integration with other reconstructive methods.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
POLLUTION, A RELEVANT EXPOSOME FACTOR IN SKIN AGING AND THE ROLE OF MULTI-BENEFIT PHOTOPROTECTION.
IF 3.8 Q1 DERMATOLOGY Pub Date : 2025-02-20 DOI: 10.1016/j.ad.2024.11.025
J Santamaria, Y Gilaberte, L Prudkin, J Piquero-Casals

Skin aging is a complex, continuous, multifactorial process resulting from cumulative morphological and functional changes in the skin over time.This happens because of 2 processes: intrinsic and extrinsic skin aging. Intrinsic skin aging occurs naturally over time and reflects each person's genetic makeup, or heredity. Extrinsic skin aging, on the other hand, is due to exposomal factors, such as solar radiation, air pollution, tobacco or nutrition, being the first 2 the most important of all. Exposure to air pollutants, primarily gases such as ground-level ozone and particulate matter, can accelerate the process via 4 key mechanisms: reactive oxygen species generation, inflammation, skin microbiome disruption, and aryl hydrocarbon receptor activation. Regarding solar radiation, all wavelengths reaching the Earth's surface have an impact on the skin, having a synergistic effect with air pollution ("photo-pollution"). Here, we discuss this phenomenon and mitigation strategies, including sunscreens, cosmetics with film-forming plus antioxidant ingredients, and oral supplementation.

{"title":"POLLUTION, A RELEVANT EXPOSOME FACTOR IN SKIN AGING AND THE ROLE OF MULTI-BENEFIT PHOTOPROTECTION.","authors":"J Santamaria, Y Gilaberte, L Prudkin, J Piquero-Casals","doi":"10.1016/j.ad.2024.11.025","DOIUrl":"https://doi.org/10.1016/j.ad.2024.11.025","url":null,"abstract":"<p><p>Skin aging is a complex, continuous, multifactorial process resulting from cumulative morphological and functional changes in the skin over time.This happens because of 2 processes: intrinsic and extrinsic skin aging. Intrinsic skin aging occurs naturally over time and reflects each person's genetic makeup, or heredity. Extrinsic skin aging, on the other hand, is due to exposomal factors, such as solar radiation, air pollution, tobacco or nutrition, being the first 2 the most important of all. Exposure to air pollutants, primarily gases such as ground-level ozone and particulate matter, can accelerate the process via 4 key mechanisms: reactive oxygen species generation, inflammation, skin microbiome disruption, and aryl hydrocarbon receptor activation. Regarding solar radiation, all wavelengths reaching the Earth's surface have an impact on the skin, having a synergistic effect with air pollution (\"photo-pollution\"). Here, we discuss this phenomenon and mitigation strategies, including sunscreens, cosmetics with film-forming plus antioxidant ingredients, and oral supplementation.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143475977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Actas dermo-sifiliograficas
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1